{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:02:52Z","timestamp":1775746972829,"version":"3.50.1"},"reference-count":27,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5582\/irdr.2016.01037","type":"journal-article","created":{"date-parts":[[2016,10,23]],"date-time":"2016-10-23T22:07:42Z","timestamp":1477260462000},"page":"238-243","source":"Crossref","is-referenced-by-count":9,"title":["The Government's role in regulating, coordinating, and standardizing the response to Alzheimer's disease: Anticipated international cooperation in the area of intractable and rare diseases"],"prefix":"10.5582","volume":"5","author":[{"given":"Qi","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Social Medicine and Medical Service Management, School of Public Health, Shandong University"},{"name":"Department of Surgery, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Song","sequence":"additional","affiliation":[{"name":"Graduate School of Frontier Sciences, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Medical Service Management, School of Public Health, Shandong University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, K\u00fcgler S, Van Leuven F. Alzheimer's disease: Old problem, new views from transgenic and viral models. Biochim Biophys Acta. 2010; 1802:808-818.","DOI":"10.1016\/j.bbadis.2010.03.005"},{"key":"2","unstructured":"2. World Health Organization. World report on Ageing and Health. 2015. http:\/\/www.who.int\/ageing\/publications\/world-report-2015\/en\/ (accessed June 14, 2016)."},{"key":"3","unstructured":"3. Alzheimer's Disease International. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. 2015. http:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2015.pdf (accessed June 14, 2016)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W. Intravenous immunoglobulins as a treatment for Alzheimer's disease: Rationale and current evidence. Drugs. 2010; 70:513-528.","DOI":"10.2165\/11533070-000000000-00000"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013; 9:63-75.e2.","DOI":"10.1016\/j.jalz.2012.11.007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Schindler RJ. Study design considerations: Conducting global clinical trials in early Alzheimer's disease. J Nutr Health Aging. 2010; 14:312-314.","DOI":"10.1007\/s12603-010-0071-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: Clinical trials and drug development. Lancet Neurol. 2010; 9:702-716.","DOI":"10.1016\/S1474-4422(10)70119-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Humbert IA, McLaren DG, Kosmatka K, Fitzgerald M, Johnson S, Porcaro E, Kays S, Umoh EO, Robbins J. Early deficits in cortical control of swallowing in Alzheimer's disease. J Alzheimers Dis. 2010; 19:1185-1197.","DOI":"10.3233\/JAD-2010-1316"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yasue M, Sugiura S, Uchida Y, Otake H, Teranishi M, Sakurai T, Toba K, Shimokata H, Ando F, Otsuka R, Nakashima T. Prevalence of sinusitis detected by magnetic resonance imaging in subjects with dementia or Alzheimer's disease. Curr Alzheimer Res. 2015; 12:1006-1011.","DOI":"10.2174\/1567205012666150710105152"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Moritoyo T. New and future treatments for neurological disorders - Knowledge essential to daily clinics and future prospects. Topics: 2. Dementia. Nihon Naika Gakkai Zasshi. 2013; 102:1916-1922. (in Japanese)","DOI":"10.2169\/naika.102.1916"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Moritoyo T. Accelerating regulatory science initiatives for the development of drugs for Alzheimer's disease in Japan. Clin Ther. 2015; 37:1622-1626.","DOI":"10.1016\/j.clinthera.2015.04.014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2012; 8(1 Suppl):1-68.","DOI":"10.1016\/j.jalz.2011.09.172"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008; 27:685-691.","DOI":"10.1002\/jmri.21049"},{"key":"14","unstructured":"14. Landmark 10-year Alzheimer's study increases pace of discovery. http:\/\/www.alz.org\/documents_custom\/071715_adni.pdf (accessed June 24, 2016)"},{"key":"15","unstructured":"15. Cooperation advances Alzheimer's disease prevention research. http:\/\/alz.org\/documents_custom\/cap_nature_news_release_092915.pdf (accessed June 20, 2016)"},{"key":"16","unstructured":"16. About the Alzheimer's Association. http:\/\/www.alz.org\/about_us_about_us_.asp (accessed February 20, 2016)"},{"key":"17","unstructured":"17. The Alzheimer's Association. Alzheimer's Association Annual Report. 2015. https:\/\/www.alz.org\/annual_report\/downloads\/annual-report.pdf#page=3 (accessed June 20, 2016)"},{"key":"18","unstructured":"18. The Alzheimer's Association. Transforming Alzheimer's Disease Therapies Through Collaboration. https:\/\/c-path. org\/wp-content\/uploads\/2015\/11\/Hendrix-Transforming-AD-Therapies.pdf (accessed March 4, 2016)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, Middleton L, Russ TC, Deary IJ, Campbell H, Wang W, Rudan I; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: A systematic review and analysis. Lancet. 2013; 381:2016-2023.","DOI":"10.1016\/S0140-6736(13)60221-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tola-Arribas MA, Yugueros MI, Garea MJ, Ortega-Val\u00edn F, Cer\u00f3n-Fern\u00e1ndez A, Fern\u00e1ndez-Malvido B, San Jos\u00e9-Gallegos A, Gonz\u00e1lez-Touya M, Botr\u00e1n-Velicia A, Iglesias-Rodr\u00edguez V, D\u00edaz-G\u00f3mez B. Prevalence of dementia and subtypes in Valladolid, northwestern Spain: The DEMINVALL study. PLoS One. 2013; 8:e77688.","DOI":"10.1371\/journal.pone.0077688"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement. 2014; 10:1-9.","DOI":"10.1016\/j.jalz.2013.01.012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Santana I, Farinha F, Freitas S, Rodrigues V, Carvalho \u00c5. The epidemiology of dementia and Alzheimer disease in Portugal: Estimations of prevalence and treatment-costs. Acta Med Port. 2015; 28:182-188.","DOI":"10.20344\/amp.6025"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer's disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis. 2015; 50:71-76.","DOI":"10.3233\/JAD-150778"},{"key":"24","unstructured":"24. Clinical Pathway for Alzheimer's Disease in China (CPAD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01779310 (accessed June 4, 2016)."},{"key":"25","unstructured":"25. The National Health and Family Planning Commission (NHFPC) implemented the clinical pathway for Alzheimer's Disease in China in April 2016. http:\/\/www.nhfpc.gov.cn\/yzygj\/s3593\/201604\/efa3826fbde44dc789e4420c6c57daeb.shtml (accessed May 4, 2016)."},{"key":"26","unstructured":"26. The clinical pathway for Alzheimer's disease in China. http:\/\/www.cma.org.cn\/attachment\/2016425\/1461563271534.docx (accessed May 4, 2016)."},{"key":"27","unstructured":"27. European Medicines Agency. Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176827.pdf (accessed May 12, 2016)."}],"container-title":["Intractable & Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/4\/5_2016.01037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T01:54:15Z","timestamp":1498355655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/4\/5_2016.01037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2016.01037","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}